Literature DB >> 14159455

THE MICRODETERMINATION OF BIOLOGICAL COPPER WITH OXALYLDIHYDRAZIDE.

R N BEALE, D CROFT.   

Abstract

Methods are described for the determination of microgram quantities of biological copper in aqueous medium as the intensely coloured oxalyldihydrazide-acetaldehyde complex (molar extinction coefficient 23,000 to 23,500). The methods are applicable on a routine basis to any biological material, in particular to serum, urine, or tissues, such as liver, brain, or kidney. In the case of urine a simple semi-quantitative screening method is also described. For quantitative work copper is liberated from serum by acid extraction and protein precipitation, and from urine and tissues by a rapid wet-ashing procedure. Recoveries of added copper from urine are quantitative. Precision is high although day-to-day control with standards and blanks is desirable. The methods are applied in an investigation of the diurnal variations in a normal man and in two cases of Wilson's disease.

Entities:  

Keywords:  BLOOD; COPPER; HEPATOLENTICULAR DEGENERATION; HYDRAZINES; MICROCHEMISTRY; OXALATES; PERIODICITY; URINE

Mesh:

Substances:

Year:  1964        PMID: 14159455      PMCID: PMC480736          DOI: 10.1136/jcp.17.3.260

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  1 in total

1.  Studies on copper metabolism I. A method for the determination of copper in whole blood, red blood cells, and plasma.

Authors:  C J GUBLER; M E LAHEY; H ASHENBRUCKER; G E CARTWRIGHT; M M WINTROBE
Journal:  J Biol Chem       Date:  1952-05       Impact factor: 5.157

  1 in total
  3 in total

1.  Micro determination of plasma and erythrocyte copper by atomic absorption spectrophotometry.

Authors:  J Blomfield; R A Macmahon
Journal:  J Clin Pathol       Date:  1969-03       Impact factor: 3.411

2.  Leucodystrophy in mink.

Authors:  H A Andersen; B Palludan
Journal:  Acta Neuropathol       Date:  1968-11-01       Impact factor: 17.088

3.  Copper metabolism in American retinitis pigmentosa patients.

Authors:  M F Marmor; J W Nelson; A S Levin
Journal:  Br J Ophthalmol       Date:  1978-03       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.